A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Conditions : Metabolic Dysfunction-associated Steatohepatitis Interventions : Drug: Efimosfermin alfa; Drug: Placebo Sponsors : GlaxoSmithKline Not yet recruiting
Read the full article3d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
Comprehensive study finds no link between mobile phones and brain cancer
theconversation.com·1h agoNew CRISPR Tool Enables Control of Ribosomal RNA to Target Protein-Related Diseases
scitechdaily.com·1h ago

Comments
Sign in to join the conversation.
No comments yet. Be the first.